Clearstead Trust LLC Makes New Investment in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clearstead Trust LLC purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,727 shares of the medical equipment provider’s stock, valued at approximately $583,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Connecticut Wealth Management LLC increased its position in Intuitive Surgical by 4.4% during the 4th quarter. Connecticut Wealth Management LLC now owns 1,081 shares of the medical equipment provider’s stock valued at $365,000 after purchasing an additional 46 shares during the period. National Bank of Canada FI increased its holdings in shares of Intuitive Surgical by 72.2% in the 4th quarter. National Bank of Canada FI now owns 359,965 shares of the medical equipment provider’s stock valued at $119,091,000 after acquiring an additional 150,897 shares during the period. TCG Advisory Services LLC raised its position in shares of Intuitive Surgical by 4,938.9% in the 4th quarter. TCG Advisory Services LLC now owns 66,715 shares of the medical equipment provider’s stock worth $22,507,000 after acquiring an additional 65,391 shares in the last quarter. First National Trust Co raised its position in shares of Intuitive Surgical by 3.8% in the 4th quarter. First National Trust Co now owns 3,127 shares of the medical equipment provider’s stock worth $1,055,000 after acquiring an additional 115 shares in the last quarter. Finally, AJOVista LLC purchased a new stake in shares of Intuitive Surgical during the 4th quarter worth $200,000. 83.64% of the stock is currently owned by institutional investors.

Insider Activity at Intuitive Surgical

In other news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,168,656.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 226,928 shares of company stock worth $87,833,828. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 1.0 %

ISRG traded up $3.71 during midday trading on Friday, hitting $381.36. 1,028,858 shares of the company were exchanged, compared to its average volume of 1,492,254. The company’s 50 day simple moving average is $385.40 and its 200 day simple moving average is $349.30. The firm has a market capitalization of $135.27 billion, a price-to-earnings ratio of 68.84, a price-to-earnings-growth ratio of 4.88 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same period last year, the company earned $1.00 earnings per share. Intuitive Surgical’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on ISRG shares. Citigroup boosted their target price on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Jefferies Financial Group upped their price target on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Truist Financial raised their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Mizuho boosted their target price on Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Finally, Barclays raised their price target on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.